Lidokainklorid B. Braun

Lidocaine Hydrochloride, the active ingredient in Lidokainklorid B. Braun, is a local anesthetic presented as a sterile solution for epidural use. It provides reversible nerve block for surgical, obstetric and other procedural pain management in adult patients. GNH USA supplies Lidokainklorid B. Braun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Lidokainklorid B. Braun is a local anesthetic used in the epidural pathway to achieve regional analgesia. - Epidural anesthesia: Produces loss of sensation in the lower body for surgical or obstetric procedures. - Intra‑operative pain control: Provides analgesia during major abdominal or orthopedic surgery. - Obstetric analgesia: Relieves labor pain while preserving maternal consciousness and motor function.

Lidokainklorid B. Braun may cause a range of adverse reactions.

Common Side Effects: - Tingling or numbness at the injection site - Light‑headedness or dizziness - Nausea or vomiting - Transient hypotension - Metallic taste in the mouth - Headache

Serious or Rare Side Effects: - Seizures or convulsions - Cardiac arrhythmias, including ventricular tachycardia - Respiratory depression or arrest - Methemoglobinemia - Severe allergic reaction (anaphylaxis) - Cardiovascular collapse

When using Lidokainklorid B. Braun, clinicians should observe several safety measures. - Assess patient allergy: Verify no known hypersensitivity to amide‑type local anesthetics. - Evaluate cardiac history: Use caution in patients with conduction disorders or heart disease. - Monitor dosage: Avoid exceeding recommended maximum cumulative dose to reduce toxicity risk. - Observe neurologic status: Watch for signs of central nervous system toxicity such as tinnitus or confusion. - Store below 25°C: Keep in the original container, protect from light and moisture.

Lidokainklorid B. Braun can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): Increased risk of cardiotoxicity and arrhythmias. - Beta‑blockers combined with high‑dose lidocaine: May potentiate bradycardia and hypotension.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): May raise plasma lidocaine levels. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): Potential additive effect on bleeding risk. - General anesthetics (e.g., propofol, volatile agents): May enhance central nervous system depression.